Compounds of formula (I) and novel uses of compounds of formula (I), such as for flavour compositions. New preparations and new methods using compounds of formula (I).

The present disclosure provides a process for the preparation of compounds of formula (III),

##STR00001##

compounds of formula (V),

##STR00002##

and corresponding salts of formula (IV).

##STR00003##

The compounds made by the methods and processes of the invention are particularly useful for administration in humans and animals.

The present disclosure provides a process for the preparation of compounds of formula (III),

##STR00001##

compounds of formula (V),

##STR00002##

and corresponding salts of formula (IV).

##STR00003##

The compounds made by the methods and processes of the invention are particularly useful for administration in humans and animals.

The present disclosure provides compounds of Formula (VIA), Formula (IIIA), Formula (IVA), and Formula (VA). The compounds are prodrugs of alpha-ketoglutarate, alpha-ketobutryrate, alpha-ketoisovalerate, and alpha-ketoisohexanoate, which are useful in treating or preventing age related diseases, disorders, or conditions. ##STR00001##

An object of the present invention is to provide a chemical liquid purification method which makes it possible to obtain a chemical liquid having excellent defect inhibition performance. Another object of the present invention is to provide a chemical liquid. The chemical liquid purification method according to an embodiment of the present invention is a chemical liquid purification method including obtaining a chemical liquid by purifying a substance to be purified containing an organic solvent, in which a content of the stabilizer in the substance to be purified with respect to the total mass of the substance to be purified is equal to or greater than 0.1 mass ppm and less than 100 mass ppm.

The present invention describes a process for obtaining a biolubricant from vegetable oil, which comprises the steps of (a) esterification reaction of the product of vegetable oil hydrolysis using a branched aliphatic alcohol; (b) epoxidation reaction of the esters obtained in step (a); and (c) nucleophilic substitution reaction of the epoxidated esters obtained in step (b) using a branched aliphatic alcohol. The present invention also describes a biolubricant obtained from the process. More specifically, a biolubricant is described that is produced from a ricinoleic fatty acid, whose formula is illustrated in FIG. 1 of the present invention, and where R.sub.1 is a hydroxyl or it is from the formula R.sub.3COO.sup.−, with R.sub.3 being an alkyl radical C.sub.1-C.sub.3, preferably a methyl radical; and R.sub.2 consists of a straight chain of hydrocarbons C.sub.4-C.sub.8 and a branched chain of hydrocarbons C.sub.1-C.sub.3.

The present invention describes a process for obtaining a biolubricant from vegetable oil, which comprises the steps of (a) esterification reaction of the product of vegetable oil hydrolysis using a branched aliphatic alcohol; (b) epoxidation reaction of the esters obtained in step (a); and (c) nucleophilic substitution reaction of the epoxidated esters obtained in step (b) using a branched aliphatic alcohol. The present invention also describes a biolubricant obtained from the process. More specifically, a biolubricant is described that is produced from a ricinoleic fatty acid, whose formula is illustrated in FIG. 1 of the present invention, and where R.sub.1 is a hydroxyl or it is from the formula R.sub.3COO.sup.−, with R.sub.3 being an alkyl radical C.sub.1-C.sub.3, preferably a methyl radical; and R.sub.2 consists of a straight chain of hydrocarbons C.sub.4-C.sub.8 and a branched chain of hydrocarbons C.sub.1-C.sub.3.

There is provided a fluorine-containing ether compound represented by the following formula. R.sup.1—R.sup.2—CH.sub.2—R.sup.3—CH.sub.2—OCH.sub.2CH(OH)CH.sub.2O—CH.sub.2—R.sup.3—CH.sub.2—R.sup.4—R.sup.5 (in the formula. R.sup.3 represents a perfluoropolyether chain; R.sup.2 and R.sup.4 represent a divalent linking group having a polar group; R.sup.1 and R.sup.5 represent a terminal group bonded to an oxygen atom of R.sup.2 or R.sup.4; and at least one of R.sup.1 and R.sup.5 is any one selected from the group consisting of an alkenyl group having 2 to 8 carbon atoms, an alkynyl group having 3 to 8 carbon atoms, an aromatic hydrocarbon-containing group, and an aromatic heterocycle-containing group).

There is provided a fluorine-containing ether compound represented by the following formula. R.sup.1—R.sup.2—CH.sub.2—R.sup.3—CH.sub.2—OCH.sub.2CH(OH)CH.sub.2O—CH.sub.2—R.sup.3—CH.sub.2—R.sup.4—R.sup.5 (in the formula. R.sup.3 represents a perfluoropolyether chain; R.sup.2 and R.sup.4 represent a divalent linking group having a polar group; R.sup.1 and R.sup.5 represent a terminal group bonded to an oxygen atom of R.sup.2 or R.sup.4; and at least one of R.sup.1 and R.sup.5 is any one selected from the group consisting of an alkenyl group having 2 to 8 carbon atoms, an alkynyl group having 3 to 8 carbon atoms, an aromatic hydrocarbon-containing group, and an aromatic heterocycle-containing group).

The present specification discloses tripartite androgen receptor eliminators (AREs), pharmaceutical compositions and medicaments comprising such AREs, methods and uses for such AREs and compositions and medicaments, and methods and uses for AREs and compositions and medicaments for treating an androgen receptor signaling-mediated condition, disease or disorder.